Weight & metabolism

Retatrutide

LY3437943, triple agonist

Retatrutide is an investigational Eli Lilly drug that activates GIP, GLP-1 and glucagon receptors at once. It has produced large weight loss in phase 3 trials but is not FDA-approved.

Key facts

  • Commonly discussed for: weight loss beyond current GLP-1 drugs.
  • Evidence (B): The phase 3 TRIUMPH-1 trial (2,339 adults, 80 weeks, published in NEJM in September 2026) reported 25.0% average weight loss at the highest dose versus 3.9% with placebo (intention-to-treat; Lilly's topline efficacy figure was 28.3%). Graded B because it is not yet approved.
  • FDA status: In FDA trials. As of November 2026 retatrutide is not FDA-approved; Lilly said in July 2026 it plans to submit for FDA approval in the first quarter of 2027, and it runs a narrow compassionate-use program.
  • Legitimate access: Clinical trial only.
  • Last reviewed: October 1, 2026.

Read the deep dives

Common questions

Is retatrutide FDA approved?

No. As of November 2026 retatrutide is investigational and not FDA-approved for any use. No pharmacy can legally sell it as an approved medicine.

When will retatrutide be FDA approved?

Lilly said on July 23, 2026 that it plans to submit retatrutide to the FDA in the first quarter of 2027. A standard review takes about 10 to 12 months, so a decision is most likely in late 2027 to early 2028, if the FDA approves it.

Can I get retatrutide before approval?

Only through a clinical trial or Lilly’s limited early access program, opened in August 2026 for a narrow group of patients with severe obesity and requested by their physician. Products sold online as "research" retatrutide are not that program.

Sources